Nefazodone in Patients With Treatment-Refractory Posttraumatic Stress Disorder
J Clin Psychiatry 2000;61(3):203-208
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Posttraumatic stress disorder (PTSD)
is a highly prevalent and often chronic disorder among combat
veterans, persisting in as many as 15% of Vietnam veterans for at
least 20 years. Treatment response in veterans with
combat-related PTSD has been disappointing. Although anxiolytics,
anticonvulsants, antipsychotics, and antidepressants have been
tried, none has been consistently associated with improvement in
all primary symptom domains (i.e., intrusive recollections,
avoidance/numbing, and hyperarousal). This open-label study
evaluated the use of nefazodone in a group of Vietnam veterans
with chronic, treatment-refractory symptoms of PTSD.
Method: Male outpatients with DSM-IV PTSD who
had failed a minimum of 3 previous medication trials were
eligible for the study. Nineteen Vietnam combat veterans entered
the study and were treated with nefazodone, 100-600 mg/day, for
12 weeks. PTSD symptoms, anxiety, depression, sleep, sexual
functioning, and adverse events were assessed weekly.
Results: Severity of depression lessened, as did
PTSD symptoms of intrusive recollections, avoidance, and
hyperarousal. Depressive symptom severity as measured by the Beck
Depression Inventory decreased by a mean of 30%. Similarly, there
was an overall drop in the intensity of PTSD symptoms as measured
by the Clinician Administered PTSD Scale of 32% with a 26%
improvement for symptoms of intrusion, 33% for avoidance, and 28%
for arousal. In addition, improvements in sleep and sexual
functioning were reported. The mean daily dose of nefazodone
after 12 weeks was 430 mg (range, 200-600 mg/day). The most
frequently reported side effects were headaches (53%), dry mouth
(42%), and diarrhea (42%), but side effects tended to be mild and
Conclusion: In this group of Vietnam veterans
with chronic treatment-refractory PTSD and multiple comorbid Axis
I psychiatric disorders, nefazodone was well tolerated and
effective. Larger, controlled studies are warranted.